111 related articles for article (PubMed ID: 29465167)
1. Computer Simulations Reveal a Novel Blocking Mode of the hERG Ion Channel by the Antiarrhythmic Agent Clofilium.
Șterbuleac D; Maniu CL
Mol Inform; 2018 Jul; 37(6-7):e1700142. PubMed ID: 29465167
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
3. In vivo targeting of ERG potassium channels in mice and dogs by a positron-emitting analogue of fluoroclofilium.
Kim SW; Yang SD; Ahn BJ; Park JH; Lee DS; Gessner G; Heinemann SH; Herdering W; Yu KH
Exp Mol Med; 2005 Aug; 37(4):269-75. PubMed ID: 16155403
[TBL] [Abstract][Full Text] [Related]
4. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs.
Perry M; Stansfeld PJ; Leaney J; Wood C; de Groot MJ; Leishman D; Sutcliffe MJ; Mitcheson JS
Mol Pharmacol; 2006 Feb; 69(2):509-19. PubMed ID: 16291873
[TBL] [Abstract][Full Text] [Related]
5. Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
Louvel J; Carvalho JF; Yu Z; Soethoudt M; Lenselink EB; Klaasse E; Brussee J; Ijzerman AP
J Med Chem; 2013 Dec; 56(23):9427-40. PubMed ID: 24224763
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241.
Gessner G; Heinemann SH
Br J Pharmacol; 2003 Jan; 138(1):161-71. PubMed ID: 12522086
[TBL] [Abstract][Full Text] [Related]
7. An antiarrhythmic agent as a promising lead compound for targeting the hEAG1 ion channel in cancer therapy: insights from molecular dynamics simulations.
Șterbuleac D; Maniu CL
Chem Biol Drug Des; 2016 Nov; 88(5):683-689. PubMed ID: 27254790
[TBL] [Abstract][Full Text] [Related]
8. Cryo-EM Structure of K
Asai T; Adachi N; Moriya T; Oki H; Maru T; Kawasaki M; Suzuki K; Chen S; Ishii R; Yonemori K; Igaki S; Yasuda S; Ogasawara S; Senda T; Murata T
Structure; 2021 Mar; 29(3):203-212.e4. PubMed ID: 33450182
[TBL] [Abstract][Full Text] [Related]
9. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
Witchel HJ; Dempsey CE; Sessions RB; Perry M; Milnes JT; Hancox JC; Mitcheson JS
Mol Pharmacol; 2004 Nov; 66(5):1201-12. PubMed ID: 15308760
[TBL] [Abstract][Full Text] [Related]
10. Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia.
Wan H; Selvaggio G; Pearlstein RA
PLoS One; 2020; 15(11):e0234946. PubMed ID: 33147278
[TBL] [Abstract][Full Text] [Related]
11. Probing the molecular basis of hERG drug block with unnatural amino acids.
Macdonald LC; Kim RY; Kurata HT; Fedida D
Sci Rep; 2018 Jan; 8(1):289. PubMed ID: 29321549
[TBL] [Abstract][Full Text] [Related]
12. Block of the inactivating potassium channel by clofilium and hydroxylamine depends on the sequence of the pore region.
Yool AJ
Mol Pharmacol; 1994 Nov; 46(5):970-6. PubMed ID: 7969088
[TBL] [Abstract][Full Text] [Related]
13. A novel hypothesis for the binding mode of HERG channel blockers.
Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
[TBL] [Abstract][Full Text] [Related]
14. Revealing Molecular Determinants of hERG Blocker and Activator Binding.
Dickson CJ; Velez-Vega C; Duca JS
J Chem Inf Model; 2020 Jan; 60(1):192-203. PubMed ID: 31880933
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
Schmidtke P; Ciantar M; Theret I; Ducrot P
J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
[TBL] [Abstract][Full Text] [Related]
16. Molecular determinants of loperamide and N-desmethyl loperamide binding in the hERG cardiac K
Vaz RJ; Kang J; Luo Y; Rampe D
Bioorg Med Chem Lett; 2018 Feb; 28(3):446-451. PubMed ID: 29274816
[TBL] [Abstract][Full Text] [Related]
17. The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Ryu S; Imai YN; Oiki S
Bioorg Med Chem Lett; 2013 Jul; 23(13):3848-51. PubMed ID: 23711922
[TBL] [Abstract][Full Text] [Related]
18. TSSF-hERG: A machine-learning-based hERG potassium channel-specific scoring function for chemical cardiotoxicity prediction.
Meng J; Zhang L; Wang L; Li S; Xie D; Zhang Y; Liu H
Toxicology; 2021 Dec; 464():153018. PubMed ID: 34757159
[TBL] [Abstract][Full Text] [Related]
19. Towards a Structural View of Drug Binding to hERG K
Vandenberg JI; Perozo E; Allen TW
Trends Pharmacol Sci; 2017 Oct; 38(10):899-907. PubMed ID: 28711156
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of hERG-neutral antihypertensive oxazalone and imidazolone derivatives.
Aksoydan B; Kantarcioglu I; Erol I; Salmas RE; Durdagi S
J Mol Graph Model; 2018 Jan; 79():103-117. PubMed ID: 29156380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
